Phase II Trial of Ribociclib in Combination With Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)

Trial Profile

Phase II Trial of Ribociclib in Combination With Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Oct 2017

At a glance

  • Drugs Everolimus (Primary) ; Ribociclib (Primary)
  • Indications Leiomyosarcoma; Liposarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Oct 2017 Status changed from not yet recruiting to recruiting.
    • 12 Jul 2017 Planned initiation date changed from 1 Jun 2017 to 1 Sep 2017.
    • 06 Jun 2017 Planned initiation date changed from 1 May 2017 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top